Trial NCT04445194
Publication Yang S, Lancet, 2021
Primary outcome on the report: For the phase 1 trial, the primary outcome was the safety of the COVID-19 vaccine;Safety outcomes were the occurrence of adverse events between the first injection to 30 days after the final injection, including all adverse events, adverse events related to vaccination, adverse events at grade 3 and worse, and adverse events leading to withdrawal of participants.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.